Project CASK committed $250,000 to a cross-institutional collaboration between Dr. Hans-Jurgen Kreienkamp at UKE Hamburg and Dr. ChangHui Pak at UMass Amherst. Their study targets the CASK-Liprin-alpha interaction in pontocerebellar hypoplasia, testing a compound that may halt cerebellar cell death. A second major therapeutic avenue alongside gene therapy.